TECFIDERA

Type: Keyphrase
Name: TECFIDERA
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

New oral MS treatment Tecfidera approved for use in Northern Ireland

The Northern Ireland Health and Social Care Board has announced that Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in Northern Ireland. The Board reached its decision after reviewing the evidence on the ... [Published MS News - Aug 22 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Pharma ETF Investing 101

With the year coming to an end, the worst of the patent cliff faced by the pharmaceutical sector in recent times is over. Although genericization will continue, the major patent expiries are over and done with.Many companies which had faced generic headwinds ... [Published Yahoo! Finance - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

dimethyl fumarate (Tecfidera)

Pharmacy Author:Omudhome Ogbru, PharmDDr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. ... [Published MedicineNet.com - Aug 20 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 2 reports

US FDA approves Biogen’s MS drug

Singapore: The US food and Drug Administration (FDA) has approved Biogen's multiple sclerosis (MS) drug, Plegridy (peginterferon beta-1a). The drug is for relapsing forms of MS, taken once every two weeks. The treatment, which has got the thumbs-up based ... [Published Bio Spectrum Asia - Aug 20 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 5 reports

Biogen twice-monthly MS drug approved

Share this article: The FDA has given the go-ahead to Biogen Idec's twice-a-month MS treatment Plegridy (peginterferon beta-1a). The approval makes this the only pegylated beta-interferon drug approved for relapsing multiple sclerosis. The injectable ... [Published Medical Marketing And Media - Aug 18 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 2 reports

Solid quarter for Merck KGaA but Rebif under pressure

Merck KGaA has posted a reasonable set of financials for the second quarter, although competition from oral therapies is beginning to hurt sales of the German firm’s multiple sclerosis drug Rebif.Net income was down 4.1% to 303.3 million euros, while ... [Published Pharma Times - Aug 13 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 2 reports

Denmark's Forward Pharma to launch IP attack on Biogen Idec's MS superstar Tecfidera

Biogen Idec's ( $BIIB ) multibillion-selling multiple sclerosis drug Tecfidera is grabbing market share left and right, but Denmark's Forward Pharma says it has a plan to take on the monster seller with its own product. It says it is looking at a $200 ... [Published FiercePharma - Aug 11 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 1, Authorised

First reported Aug 07 2014 - Updated Aug 07 2014 - 4 reports

TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta

MISSISSAUGA, ON, Aug. 7, 2014 (Canada NewsWire via COMTEX) -- ... [Published Individual.com - Aug 07 2014]
Entities: TECFIDERA, Comtex, Canada
First reported Aug 01 2014 - Updated Aug 01 2014 - 2 reports

Biogen shares dip on hurdle in Germany

Shares of Biogen Idec dropped slightly Friday after the biopharma giant hit a second hurdle in Europe over its multiple sclerosis drug Tecfidera, a product Biogen hopes to soon produce in the Triangle.German regulators determined that Tecfidera provided ... [Published Business First of Buffalo - Aug 01 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 2 reports

Can Biogen Idec Take Wing With Tecfidera?

By William Meyers :Biogen Idec (NASDAQ: BIIB ) generates most of its revenue from drugs for MS ( multiple sclerosis ), but also receives substantial sums from other disease indications. It recently has gained approval for its hemophilia therapies. Biogen ... [Published BioPortfolio - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 2 reports

Tecfidera not working p!!!

Hi all I'm back again my yearly or so problem check in :/ maybe you might recall me I started tecfidera in Sept, repeat MRI 7 months later showed multiple new and enhancing lesions obviously this drug is not for me eitherNot surprised this is my 4th ... [Published HealthBoards - Jul 25 2014]
Entities: TECFIDERA, Rebif, Gilenya

Quotes

"Our goal is to price this in a way that does not bias the medical decision-making process" Meeker said
...He added that as a treating neurologist, "I believe these attributes will appeal to MS patients who look for less frequent dosing with proven effectiveness"
"As a proposition for patients, it's a very attractive compound" Biogen's Vice President of Multiple Sclerosis ResearchResearch and DevelopmentDevelopment Gilmore N O'Neill told The Boston Globe...
...Avonex has to be injected weekly, while rivals such as Merck KGaA's Rebif are injected more often. "We believe Plegridy has the potential to be the leading interferon on the market" Biogen commercial chief Tony Kingsley told Reuters

More Content

All (184) | News (120) | Reports (1) | Blogs (62) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
New oral MS treatment Tecfidera approved for us... [Published MS News - Aug 22 2014]
Pharma ETF Investing 101 [Published Yahoo! Finance - Aug 21 2014]
Company Update: Biogen Idec Inc (NASDAQ:BIIB) –... [Published Jutia Group - Aug 21 2014]
Interferons vs. Copaxone: how do they compare? [Published MSology - Aug 21 2014]
Price could be key for Sanofi's new Gaucher pil... [Published FiercePharma - Aug 20 2014]
6 Biotech Stocks to Buy Now With Up to 100% Ups... [Published 24/7 Wall St - Aug 20 2014]
6 Biotech Stocks to Buy Now With Up to 100% Ups... [Published Yahoo! Xtra Business - Aug 20 2014]
dimethyl fumarate (Tecfidera) [Published MedicineNet.com - Aug 20 2014]
US FDA approves Biogen’s MS drug [Published Bio Spectrum Asia - Aug 20 2014]
FDA okays Genzyme pill for Gaucher disease [Published Boston Globe - Aug 19 2014]
Biogen Strengthens MS Portfolio with Plegridy F... [Published Nasdaq - Aug 19 2014]
Biogen Strengthens MS Portfolio with Plegridy F... [Published Zacks.com - Aug 19 2014]
Biogen twice-monthly MS drug approved [Published Medical Marketing And Media - Aug 18 2014]
Biogen Idec (Nasdaq: BIIB) Stock Gains on FDA A... [Published Money Morning - Aug 18 2014]
Biogen ready to steal market share with newly m... [Published FiercePharma - Aug 18 2014]
Biogen Idec’s Plegridy gains US approval for mu... [Published Pharma Letter - Aug 18 2014]
FDA approves Biogen Idec's long-acting MS therapy [Published PMLive - Aug 18 2014]
FDA approves Biogen’s long-acting MS drug [Published Pharmafocus - Aug 18 2014]
Biogen scores fresh MS advance with blockbuster... [Published FierceBiotech - Aug 18 2014]
Biogen Idec finally gets approval for MS drug P... [Published Examiner.com - Aug 17 2014]
FDA Approves Multiple Sclerosis Drug Plegridy [Published Inquisitr - Aug 17 2014]
FDA approves Biogen MS drug Plegridy [Published Pharma Times - Aug 16 2014]
Market Update: Biogen Idec Inc (NASDAQ:BIIB) – ... [Published Fat Pitch Financials - Aug 16 2014]
Market Update: Biogen Idec Inc (NASDAQ:BIIB) – ... [Published Jutia Group - Aug 16 2014]
FDA approves new injectable multiple sclerosis ... [Published Boston Globe - Aug 16 2014]
UPDATE 1-Biogen wins U.S. approval of long acti... [Published Reuters - Aug 15 2014]
Supernus Finding Success, Looks Undervalued [Published Seeking Alpha - Aug 15 2014]
Rebif hit again as competition bites [Published PMLive - Aug 15 2014]
Synthetic Biologics' (SYN) CEO Jeff Riley on Q2... [Published Seeking Alpha - Aug 14 2014]
MSology at ACTRIMS-ECTRIMS – BOSTON 2014 [Published MSology - Aug 14 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
New oral MS treatment Tecfidera approved for us... [Published MS News - Aug 22 2014]
The Northern Ireland Health and Social Care Board has announced that Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in Northern Ireland. The Board reached its decision after reviewing the evidence on the ...
Interferons vs. Copaxone: how do they compare? [Published MSology - Aug 21 2014]
Beta-interferon drugs (Avonex, Betaseron/Extavia, Rebif) and Copaxone have been the mainstay of treatment for MS for over two decades. What they have in common is very modest effectiveness, and the need to be injected. But is one type of treatment better ...
MSology at ACTRIMS-ECTRIMS – BOSTON 2014 [Published MSology - Aug 14 2014]
The largest event on MS research will be the joint meeting of ACTRIMS-ECTRIMS, which will be held from September 10-13. MSology will be attending this year’s meeting in Boston. A lot of new information will be presented, so you can help us pick the ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 11 2014]
Added benefit is not proven for Dimethyl fumara... [Published MS News - Aug 11 2014]
No studies for direct comparison / Data for indirect comparison are incomplete and the analysis is unsuitableDimethyl fumarate (trade name: Tecfidera) has been approved since January 2014 for... ...
1 2 3 4 5 6 7 8 9 10 ...
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.